Evidence map›Paper›PMID 28810670›Full record

ArticleInternational health2017

Journey towards universal viral load monitoring in Maputo, Mozambique: many gaps, but encouraging signs.

Sarah Swannet, Tom Decroo, Sheila M T L de Castro, Caroline Rose, Ruggero Giuliani, Lucas Molfino, Ana W Torrens, Walter S E D Macueia, Sharon Perry, Tony Reid

Abstract read
In one paragraph

Article in International health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sarah SwannetOperational Centres Geneva and Brussels, Médecins sans Frontières, Maputo, Mozambique.
Tom DecrooOperational Research Unit, Médecins sans Frontières, Luxembourg, Luxembourg.
Sheila M T L de CastroDirection of Health in Maputo City, Ministry of Health, Maputo, Mozambique.
Caroline RoseOperational Centres Geneva and Brussels, Médecins sans Frontières, Maputo, Mozambique.
Ruggero GiulianiOperational Centres Geneva and Brussels, Médecins sans Frontières, Maputo, Mozambique.
Lucas MolfinoOperational Centres Geneva and Brussels, Médecins sans Frontières, Maputo, Mozambique.
Ana W TorrensOperational Centres Geneva and Brussels, Médecins sans Frontières, Maputo, Mozambique.
Walter S E D MacueiaOperational Centres Geneva and Brussels, Médecins sans Frontières, Maputo, Mozambique.
Sharon PerrySouthern Africa Medical Unit, Médecins sans Frontières, Cape Town, South Africa.
Tony ReidOperational Research Unit, Médecins sans Frontières, Luxembourg, Luxembourg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Viral load (VL) monitoring for people on antiretroviral therapy (ART) is extremely challenging in resource-limited settings. We assessed the VL testing scale-up in six Médecins Sans Frontières supported health centres in Maputo, Mozambique, during 2014-15. Methods: In a retrospective cohort study, routine programme data were used to describe VL testing uptake and results, and multi-variate logistical regression to estimate predictors of VL testing uptake and suppression. Results: Uptake of a first VL test was 40% (17 236/43 579). Uptake of a follow-up VL test for patients with a high first VL result was 35% (1095/3100). Factors associated with a higher uptake included: age below 15 years, longer time on ART and attending tailored service delivery platforms. Virological suppression was higher in pregnant/breastfeeding women and in community ART Group members. Patients with a high first VL result (18%; 3100/17 236) were mostly younger, had been on ART longer or had tuberculosis. Out of 1095 attending for a follow-up VL test, 678 (62%) had virological failure. Of those, less than one-third had started second line ART. Conclusion: This was the first study describing the uptake and results of VL testing scale-up in Mozambique. Identified gaps show patient and programmatic challenges. Where service delivery was customized to patient needs, VL monitoring was more successful.

Indexed as

AdolescentAdultAnti-HIV AgentsChildChild, PreschoolDrug MonitoringFemaleHIV InfectionsHumansMaleMozambiquePregnancyProgram EvaluationRetrospective StudiesViral LoadYoung AdultAnti-HIV AgentsAntiretroviral therapyHIVMozambiqueOperational researchSub-Saharan AfricaViral load monitoring

Identifiers

PMID28810670
PMCPMC5881256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.